A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Depemokimab (Primary) ; Benralizumab; Corticosteroids; Mepolizumab
- Indications Acute asthma
- Focus Registrational; Therapeutic Use
- Acronyms NIMBLE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 29 Apr 2024 Planned End Date changed from 26 Sep 2026 to 26 Sep 2025.
- 29 Apr 2024 Planned primary completion date changed from 26 Sep 2026 to 26 Sep 2025.
- 25 Apr 2024 Planned End Date changed from 25 Jul 2025 to 26 Sep 2026.